Targeting metabotropic glutamate receptors for the treatment of Parkinson's disease

  • Neurodegener Dis Manag. 2023 Aug;13(4):203-206. doi: 10.2217/nmt-2023-0016.
Philippe Huot  1  2  3
Affiliations
  • 1. Neurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), Montreal, QC, H3A 2B4, Canada.
  • 2. Department of Neurology & Neurosurgery, McGill University, Montreal, QC, H3A 2B4, Canada.
  • 3. Department of Neuroscience, Movement Disorder Clinic, Division of Neurology, McGill University Health Centre, Montreal, QC, H3A 2B4, Canada.
PMID: 37306283 DOI: 10.2217/nmt-2023-0016
Keywords
Parkinson’s disease; dyskinesia; glutamate; mGlu2 receptors; mGlu3 receptors; mGlu4 receptors; mGlu5 receptors; metabotropic glutamate receptors; parkinsonism; psychosis.
Products